Rituximab Maintenance Therapy After Autologous Stem-Cell Transplantation in Patients With Relapsed CD20(+) Diffuse Large B-Cell Lymphoma: Final Analysis of the Collaborative Trial in Relapsed Aggressive Lymphoma

PURPOSE: The standard treatment for relapsed diffuse large B-cell lymphoma (DLBCL) is salvage chemotherapy followed by high-dose therapy and autologous stem-cell transplantation (ASCT). The impact of maintenance rituximab after ASCT is not known. PATIENTS AND METHODS: In total, 477 patients with CD2...

詳細記述

保存先:
書誌詳細
主要な著者: Gisselbrecht, Christian, Schmitz, Norbert, Mounier, Nicolas, Singh Gill, Devinder, Linch, David C., Trneny, Marek, Bosly, Andre, Milpied, Noel J., Radford, John, Ketterer, Nicolas, Shpilberg, Ofer, Dührsen, Ulrich, Hagberg, Hans, Ma, David D., Viardot, Andreas, Lowenthal, Ray, Brière, Josette, Salles, Gilles, Moskowitz, Craig H., Glass, Bertram
フォーマット: Artigo
言語:Inglês
出版事項: American Society of Clinical Oncology 2012
主題:
Original Reports
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC3646314/
https://ncbi.nlm.nih.gov/pubmed/23091101
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2012.41.9416
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料